U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H28N6O3S
Molecular Weight 480.583
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SURUFATINIB

SMILES

CN(C)CCNS(=O)(=O)CC1=CC=CC(NC2=NC=CC(OC3=CC=C4NC(C)=CC4=C3)=N2)=C1

InChI

InChIKey=TTZSNFLLYPYKIL-UHFFFAOYSA-N
InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)

HIDE SMILES / InChI

Molecular Formula C24H28N6O3S
Molecular Weight 480.583
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sulfatinib (previously known as HMPL-012) was developed as a small-molecule inhibitor targeting vascular endothelial growth factor receptors 1 and 3, fibroblast growth factor receptor 1 and colony-stimulating factor 1 receptor with potential antineoplastic and anti-angiogenic activities. Sulfatinib has shown encouraging antitumor activity and manageable toxicities in patients with advanced neuroendocrine tumors (NET). The drug is participating in two ongoing phases III studies, validating the efficacy of surufatinib in patients with NETs. In addition, in November 2018, Hutchison MediPharma completed a phase II trial of sulfatinib, for the treatment of patients with biliary tract cancer. This drug is also participating in the phase II trial that is currently in recruiting status in treating advanced medullary thyroid carcinoma.

Approval Year

PubMed

PubMed

TitleDatePubMed
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
2019 Jun 15

Sample Use Guides

SULFATINIB (HMPL-012) 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:44:53 GMT 2023
Edited
by admin
on Sat Dec 16 08:44:53 GMT 2023
Record UNII
B2K5L1L8S9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SURUFATINIB
USAN   INN  
Official Name English
surufatinib [INN]
Common Name English
Surufatinib [WHO-DD]
Common Name English
BENZENEMETHANESULFONAMIDE, N-(2-(DIMETHYLAMINO)ETHYL)-3-((4-((2-METHYL-1H-INDOL-5-YL)OXY)-2-PYRIMIDINYL)AMINO)-
Systematic Name English
SURUFATINIB [USAN]
Common Name English
SULFATINIB
Common Name English
HMPL-012
Code English
N-(2-(DIMETHYLAMINO) ETHYL)-1-(3-((4-(2-METHYL-1H-INDOL-5-YLOXY) PYRIMIDIN-2-YL) AMINO) PHENYL) METHANESULFONAMIDE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 710319
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
NCI_THESAURUS C93259
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
Code System Code Type Description
PUBCHEM
52920501
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
PRIMARY
CAS
1816307-67-1
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
SUPERSEDED
USAN
HI-176
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
PRIMARY
NCI_THESAURUS
C116066
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
PRIMARY
CAS
1308672-74-3
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
PRIMARY
DRUG BANK
DB15106
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
PRIMARY
SMS_ID
100000181191
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
PRIMARY
FDA UNII
B2K5L1L8S9
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
PRIMARY
INN
10349
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545251
Created by admin on Sat Dec 16 08:44:53 GMT 2023 , Edited by admin on Sat Dec 16 08:44:53 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY